The change negotiations concerning Orion’s Kuopio plant have been concluded – the company has decided to continue to explore the outsourcing of production at the plant
22 Mar 2024
The change negotiations concerning Orion’s Kuopio plant have been concluded – the company has decided to continue to explore the outsourcing of production at the plant
ORION CORPORATION
PRESS RELEASE
22 March 2024 at 12.00 EET
The change negotiations concerning Orion’s Kuopio plant have been concluded – the company has decided to continue to explore the outsourcing of production at the plant
Orion Corporation announced on 19 February 2024 that it was evaluating the possible outsourcing of its pharmaceutical production in Kuopio, part of its Global Operations function, to an entity outside Finland. The related statutory negotiations in accordance with the Act on Co-operation within Undertakings have now been concluded.
Alternatives for the outsourcing and its personnel impacts were examined in the statutory negotiations. Orion has decided to continue to explore the outsourcing of production at the Kuopio plant. The estimated time scope is that the plant would continue to operate until at least the summer of 2026.
All ca. 40 employees included in the negotiations will be offered jobs of a comparable level at other Orion production sites in Finland. The statutory negotiations included the entire personnel in operations and functions which support production in the Kuopio plant. Other employees working in the Kuopio plant were not impacted by the statutory negotiations.
The evaluation of the outsourcing of production at the Kuopio plant has been due to the low competitiveness of the plant, low capacity utilisation, increasing quality requirements in the pharmaceutical industry, and high investment needs.
Orion’s manufacturing plant in Kuopio specialises in liquids and self-care products. Among the most widely known of the products manufactured in Kuopio are nasal sprays, cough medicines, and ear drops. These products would continue to be part of Orion’s product portfolio also in the future.
Orion’s Global Operations and Quality Management have about 1,900 employees in total. Global Operations consists of production at Orion's own plants in Espoo, Turku, Kuopio, and Salo; an external supplier network; procurement; and Fermion Oy, which manufactures active pharmaceutical ingredients in Hanko and Oulu.
Contact person:
Terhi Ormio
VP, Communications
tel. +358 10 426 4646
Publisher:
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.